1. Epigenetics Protein Tyrosine Kinase/RTK JAK/STAT Signaling Stem Cell/Wnt Autophagy
  2. JAK Autophagy
  3. Momelotinib Mesylate

Momelotinib Mesylate  (Synonyms: CYT387 Mesylate)

目录号: HY-10963

Momelotinib Mesylate (CYT387 Mesylate) 是一种 ATP 竞争性的 JAK1/JAK2 抑制剂,IC50 值分别为 11 nM/18 nM,对其选择性约是 JAK3 的 10 倍。

MCE 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务


Momelotinib Mesylate Chemical Structure

Momelotinib Mesylate Chemical Structure

CAS No. : 1056636-07-7

1.  客户无需承担相应的运输费用。

2.  同一机构(单位)同一产品试用装仅限申领一次,同一机构(单位)一年内


3.  试用装只面向终端客户

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Momelotinib Mesylate 的其他形式现货产品:

Other Forms of Momelotinib Mesylate:

    Momelotinib Mesylate purchased from MCE. Usage Cited in: Cancer Cell. 2018 Sep 10;34(3):439-452.e6.  [Abstract]

    Immunoblot (IB) of the indicated proteins in A549, H2009, HCC44, and H1792 cells treated with indicated concentration of Momelotinib (MMB) for 24 hr.

    查看 JAK 亚型特异性产品:

    • 生物活性

    • 实验参考方法

    • 纯度 & 产品资料

    • 参考文献


    Momelotinib Mesylate (CYT387 Mesylate) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3.

    IC50 & Target[1]


    11 nM (IC50)


    18 nM (IC50)


    155 nM (IC50)

    (In Vitro)

    Momelotinib Mesylate is an inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, appr 10-fold selectivity versus JAK3. Momelotinib inhibits the proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated by IL-3 with IC50 of 1400 nM. Furthermore, Momelotinib also causes the inhibition of cell proliferation in cell lines constitutively activated by JAK2 or MPL signaling, including Ba/F3-MPLW515L cells, CHRF-288-11 cells and Ba/F3-TEL-JAK2 cells with IC50 of 200 nM, 1 nM and 700 nM, respectively. In addition, Momelotinib has been shown to inhibit erythroid colony growth in vitro from JAK2V617F-positive PV patients with similar potency with IC50 of 2 μM-4 μM[1]. Momelotinib inhibits PI3K/AKT and Ras/MAPK signaling induced by IL-6 and IGF-1. Moreover, Momelotinib induces apoptosis as a single agent and synergizes with the conventional anti-MM therapies bortezomib and melphalan in primary multiple myeloma (MM) cells[2].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    (In Vivo)

    In a murine MPN model, Momelotinib normalizes white cell counts, hematocrit, spleen size, and restores physiologic levels of inflammatory cytokines[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Clinical Trial




    CAS 号

    Room temperature in continental US; may vary elsewhere.


    Please store the product under the recommended conditions in the Certificate of Analysis.

    纯度 & 产品资料
    Cell Assay

    Ba/F3 cells expressing JAK2V617F (Ba/F3-JAK2V617F) and MPLW515L (Ba/F3-MPLW515L) mutants, as well as CHRF-288-11 (JAK2T875N) and CMK (JAK3A572V) cells are used. The TEL/JAK2 and TEL/JAK3 fusions are generated and introduced into Ba/F3 murine cells. The TEL/JAK2- or TEL/JAK3-transfected cells are cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum (FCS). Ba/F3 wild-type cells are cultured in RPMI containing 10% FCS supplemented with 5 ng/mL murine IL-3. Proliferation is measured using the Alamar Blue assay after incubating for 72 hours at 37°C with 5% CO2[1].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Administration

    On day 32 after bone marrow transplantation (when all mice exhibit severe leukocytosis and erythrocytosis), mice are assigned to 3 groups such that each group had equivalent average body weight and blood counts. Momelotinib is dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone). Subsequently, the Momelotinib/NMP mix is diluted with 0.14 M Captisol to a concentration of 6 mg/mL and further diluted with 0.1 M Captisol to a final concentration of 4 mg/mL. All 3 groups of mice (n=12 per group) are administered Momelotinib by oral gavage twice daily at 10- to 12-hour intervals from day 34 after bone marrow transplantation to day 82 (end of experiment). Mice receive NMP/Captisol without Momelotinib (0 mg/kg group), 25 mg/kg Momelotinib, or 50 mg/kg Momelotinib. At day 82 after bone marrow transplantation, all mice are euthanized for analysis except for 2 mice each from the 50 mg/kg and 25 mg/kg groups, which are taken off Momelotinib treatment and followed for 45 additional days. For assessment of the effects of Momelotinib on normal blood counts, naive Balb/c mice are administered vehicle control, or 50 mg/kg, or 100 mg/kg Momelotinib in an identical fashion for the bone marrow transplant experimental mouse cohort. Peripheral blood is drawn at day 14, 28, 42, and 56 and levels of red cells, white cells, reticulocytes, granulocytes, lymphocytes, and monocytes are analyzed[3].

    MCE has not independently confirmed the accuracy of these methods. They are for reference only.

    • 摩尔计算器

    • 稀释计算器

    The molarity calculator equation

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    质量   浓度   体积   分子量 *
    = × ×

    The dilution calculator equation

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
    × = ×
    C1   V1   C2   V2
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.


    Your information is safe with us. * Required Fields.



    * 需求量:

    * 客户姓名:


    * Email:

    * 电话:


    * 公司或机构名称:


    Bulk Inquiry

    Inquiry Information

    Momelotinib Mesylate